.jpg)
.png)
All
li{ margin-bottom: 10px; } In June of 2013, the Health Quality Research Committee was tasked by Merck and Company to perform a research project to identify and understand the barriers that exist and prevent patients from reaching their LDL-C goals as it relates to health information... more
PROGRAM OVERVIEW: Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease ACTIVITY TYPE Enduring Internet NLA ID: 2025031 ACTIVITY DATES Release Date: October 30, 2025 Expiration Date: April 30, 2026 FEE INFORMATION There is no... more
Pam Morris, MD, FNLA moderates this session featuring top experts on Women, Atherosclerosis and Lipids.
ORLANDO (March 10, 2018) – The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE)... more
Chicago, IL (Nov. 14, 2014) — The National Lipid Association (NLA), in collaboration with Guideline Central, has created a convenient pocket guide based on its recently released Recommendations for Patient-Centered Management of Dyslipidemia. The new pocket guide titled “Dyslipidemia” is a quick-... more
Founding Member of the Northeast Lipid Association A physician’s physician A true patient advocate Mentor Friend David Capuzzi, MD, PhD, FNLA, member of the National Lipid Association since 2004, leader in the Northeast Lipid Association, colleague to many, and friend passed away on... more
The Foundation of the NLA has already had an extremely eventful 2017 with many new, exciting plans for its future and direction. The Foundation Board of Directors met in January to discuss our goals, strategy and upcoming plans. The discussions at this meeting led to a new mission, vision and... more
To read about highligts from ACC, click on the link below. The highlights will cover the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk, the HOPE 3 trial, the GAUSS-3 trial, and the ACCELERATE trial.... more